| Scientific Name |
Tofacitinib
|
|---|---|
| Brand Name |
Xeljanz
|
| Risk |
Risk of Major Adverse Cardiovascular Events and Malignancies (Excluding NMSC) with Use of Xeljanz/Xeljanz XR (tofacitinib) Relative to TNFi Therapy. Safety information about monitoring and Increased risk of pulmonary embolism and overall mortality with higher dose of XELJANZ (tofacitinib) for rheumatoid arthritis.
|
| Educational Materials for Healthcare Professionals |
|
| Dear Healthcare Professional Communication (DHPC) for Healthcare Professionals |
|
| Educational Materials for Patients |
|